Madrigal Pharmaceuticals, Inc. MDGL Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$309.44M-7.3% | -$288.28M+0.3% | -$289.13M-2.6% | -$281.9M+28.0% | -$391.59M+15.9% | ||
| $1.51M+0.5% | $1.51M+2.0% | $1.48M+4.2% | $1.42M+8.4% | $1.31M+19.3% | ||
| $111.22M+13.3% | $98.13M+9.0% | $90.02M+10.2% | $81.66M+0.9% | $80.91M+1.3% | ||
| $1.62M+0.8% | $1.6M-0.9% | $1.62M-8.5% | $1.77M-5.4% | $1.87M-10.5% | ||
| $125.93M+56.1% | $80.65M-2.6% | $82.82M+14.5% | $72.33M+17.8% | $61.43M+14.1% | ||
| $37.99M+2.7% | $36.98M-39.0% | $60.6M+7.4% | $56.43M+3.7% | $54.39M+59.6% | ||
| $10.41M+97.1% | $5.28M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$307.41M+22.2% | -$395.31M+13.2% | ||
| —— | —— | $1.05M+8.0% | $974K-11.9% | $1.11M-24.4% | ||
| $1.07B+2.6% | $1.05B-11.6% | $1.18B+5.5% | $1.12B-4.7% | $1.18B+4.1% | ||
| $1.14B+5.5% | $1.08B-5.4% | $1.15B+5.6% | $1.08B+11.2% | $975.37M+13.0% | ||
| —— | —— | —— | -$38.61M+81.5% | -$208.56M+24.0% | ||
| —— | —— | —— | —— | —— | ||
| $249.67M-2.5% | $255.98M-4.1% | $266.8M+609% | $37.61M-77.9% | $170M-76.9% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | —— | ||
| $1.62M+0.8% | $1.6M-0.9% | $1.62M-8.5% | $1.77M-5.4% | $1.87M-10.5% | ||
| $10.41M+97.1% | $5.28M— | —— | —— | —— | ||
| $5.1M-14.6% | $5.97M+161% | -$9.77M+2.0% | -$9.97M+51.0% | -$20.36M+17.2% | ||
| —— | —— | —— | —— | —— | ||
| $3.56M+11.0% | $3.21M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.14B+5.5% | $1.08B-5.4% | $1.15B+5.6% | $1.08B+11.2% | $975.37M+13.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $5.4M+108% | $2.6M— | ||
| —— | —— | —— | -$308.39M+22.2% | -$396.41M+13.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Madrigal Pharmaceuticals, Inc. generate?
- Madrigal Pharmaceuticals, Inc. (MDGL) generated -$436.8M in operating cash flow over the trailing twelve months.
- What is Madrigal Pharmaceuticals, Inc.'s free cash flow?
- After $4.7M of capital expenditures, Madrigal Pharmaceuticals, Inc.'s free cash flow was -$440.3M over the trailing twelve months, up 3.7% year over year.
- Where does Madrigal Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
